Scarica l'app Stockscreener
1.39
0.00%
0.00
Dopo l'orario di chiusura:
1.41
0.02
+1.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.39
Aprire:
$1.41
Volume 24 ore:
2.43M
Relative Volume:
0.39
Capitalizzazione di mercato:
$471.36M
Reddito:
$4.47M
Utile/perdita netta:
$-71.67M
Rapporto P/E:
-5.9965
EPS:
-0.2318
Flusso di cassa netto:
$-59.58M
1 W Prestazione:
+2.96%
1M Prestazione:
+6.92%
6M Prestazione:
-13.13%
1 anno Prestazione:
+37.62%
Intervallo 1D:
$1.37
$1.42
Intervallo di 1 settimana:
$1.32
$1.49
Portata 52W:
$1.00
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Nome
Ocugen Inc
Settore
Industria
Telefono
484-328-4701
Indirizzo
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.39 | 471.36M | 4.47M | -71.67M | -59.58M | -0.2318 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Iniziato | Canaccord Genuity | Buy |
| 2026-03-11 | Iniziato | Oppenheimer | Outperform |
| 2024-10-15 | Iniziato | Maxim Group | Buy |
| 2023-03-01 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Iniziato | Mizuho | Buy |
| 2022-06-15 | Ripresa | ROTH Capital | Buy |
| 2022-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Iniziato | Noble Capital Markets | Outperform |
| 2021-06-11 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
Mostra tutto
Ocugen Inc Borsa (OCGN) Ultime notizie
Why Did OCGN Stock Rise Today? - Stocktwits
Ocugen’s Earnings Call Highlights Risk-Reward Inflection - TipRanks
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen (OCGN) Quarterly Results: Reported EPS Misses Expectations under the Current Snapshot; Share Response: Shares Move 10.45% Up at the CloseGuidance Update - Vinanet
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen Inc (NASDAQ: OCGN) Stock Price, News & Analysis - Kalkine
Ocugen’s Phase 3 Gene Therapy Trial Targets High-Value Dry AMD Market - TipRanks
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
symbol__ Stock Quote Price and Forecast - CNN
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen (OCGN) Q2 2026 Earnings Call Transcript - AOL.com
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts - marketbeat.com
Q2 2026 Ocugen Inc Earnings Call Transcript - GuruFocus
OCUGEN INC (OCGN) Stock Chart - ChartMill
Ocugen Stock Price Forecast. Should You Buy OCGN? - StockInvest.us
Ocugen, Inc. (NASDAQ:OCGN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Janus Henderson Group (OCGN) discloses 10M-share beneficial stake in Ocugen - Stock Titan
Ocugen (OCGN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
Ocugen at Canaccord Genuity’s 46th Annual Growth Conference: late-stage push - Investing.com Canada
Research Analysts Issue Forecasts for Ocugen Q3 Earnings - MarketBeat
What is Noble Financial's Forecast for Ocugen Q3 Earnings? - MarketBeat
Hennion & Walsh Asset Management Inc. Purchases 1,553,672 Shares of Ocugen, Inc. $OCGN - MarketBeat
Ocugen (NASDAQ:OCGN) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls - Yahoo Finance
Ocugen Inc (OCGN) Stock News Today - TradingKey
State Street Corporation (NYSE: STT) reports 6.3% beneficial stake in Ocugen - Stock Titan
Ocugen Q2 Earnings Call Highlights - MarketBeat
Ocugen (NASDAQ:OCGN) Posts Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Ocugen Inc (OCGN) (Q2 2026) Earnings Call Highlights: FDA Cleara - GuruFocus
Form 8K Ocugen, Inc For: 6 August By Investing.com - Investing.com South Africa
Ocugen Inc (OCGN) (Q2 2026) Earnings Call Highlights: FDA Clearance for OCU410 Phase 3 Trial ... - Yahoo Finance
Ocugen, Inc. 2026: Revenue $1.49M, EPS ($0.07) — 10-Q Summary - TradingView
Ocugen (NASDAQ: OCGN) raises $112.5M via converts as losses hit $44.1M - Stock Titan
Ocugen, Inc. Announces Management Changes - marketscreener.com
Earnings call transcript: Ocugen posts Q2 2026 revenue beat as loss widens - Investing.com
OCGN: FDA cleared phase III for OCU410; cash runway extended to 2028 after $130M financing - TradingView
Ocugen Provides Business Update with Second Quarter 2026 Financial Results - Ocugen, Inc.
Ocugen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates - finance.yahoo.com
Ocugen, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Ocugen reports $1.49M Q2 revenue, $0.07 loss per share and $100.4M cash as of June 30, 2026 - TradingView
Ocugen: Q2 Earnings Snapshot - marketscreener.com
Ocugen Reports Q2 2026 Results, Advances OCU410 Phase 3, Secures RMAT Designation and $130 Million Financing - Quiver Quantitative
Press Release: Ocugen Provides Business Update With Second Quarter 2026 Financial Results - Moomoo
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen Inc Azioni (OCGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):